Immutep Ltd Updates Stakeholders on Business Progress

TipRanksFeb 4 20:00 ET

Immutep Limited (ASX:IMM) Is Largely Controlled by Institutional Shareholders Who Own 51% of the Company

Yahoo FinanceJan 15 17:39 ET

Immutep Reaches Enrollment Target for Non-Small Cell Lung Cancer Therapy Trial

MT NewswiresJan 5 18:39 ET

Immutep Ltd Announces Cessation of Performance Rights

TipRanksDec 17, 2024 01:38 ET

Immutep's Phase 1 Trial Shows Favorable Safety Profile of Drug Candidate for Autoimmune Disease; Shares Down 3%

MT NewswiresDec 16, 2024 20:35 ET

Immutep Dips as Safety Test for Flagship Drug IMP761 Shows No Adverse Effects

The Market HeraldDec 16, 2024 18:27 ET